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Abstract Fumarate hydratase catalyzes the stereospecific
hydration across the olefinic double bond in fumarate
leading to L-malate. The enzyme is expressed in mito-
chondrial and cytosolic compartments, and participates in
the Krebs cycle in mitochondria, as well as in regulation
of cytosolic fumarate levels. Fumarate hydratase deficien-
cy is an autosomal recessive trait presenting as metabolic
disorder with severe encephalopathy, seizures and poor
neurological outcome. Heterozygous mutations are associ-
ated with a predisposition to cutaneous and uterine
leiomyomas and to renal cancer. The crystal structure of
human fumarate hydratase shows that mutations can be
grouped into two distinct classes either affecting structural
integrity of the core enzyme architecture, or are localized
around the enzyme active site.
An interactive version of this manuscript (which may
contain additional mutations appended after acceptance of
this manuscript) may be found on the SSIEM website at:
http://www.ssiem.org/resources/structures/FH.
Abbreviations
FH Fumarate hydratase
FHD Fumarate hydratase deficiency
MCUL1 Multiple cutaneous and uterine leiomyomata
HLRC Hereditary leiomyomatosis and renal cancer
syndrome
Introduction
Fumarate hydratase (FH) and succinate dehydrogenase are
two integral enzyme components of the Krebs cycle, and
besidestheiressentialroleintheTCAcycle,canactastumour
suppressors (King et al. 2006). The FH gene codes for
fumaratehydratase(orfumarase;EC4.2.1.2),whichcatalyzes
the stereospecific, reversible hydratation of fumarate to
L-malate. The FH gene localized at 1q42.1 codes for dif-
ferentially processed, but sequence-wise identical cytosolic
and mitochondrial forms. Whereas the mitochondrial
enzyme is part of the TCA cycle, the cytosolic form is
thought to utilize fumarate derived from different sources.
Deficiency in FH activity causes an impaired energy
production by interrupting the flow of metabolites through
the Krebs cycle. Accumulation of fumarate is thought to
competitively inhibit 2-oxo-glutarate dependent dioxy-
genases that regulate hypoxia inducible factor (HIF), thus
activating oncogenic hypoxia pathways (Ratcliffe, 2007).
Due to their essential role in energy production, enzyme
deficiencies result in early onset of severe encephalopathy
(Kerrigan et al. 2000). Accordingly, autosomal recessive
fumarate hydratase deficiency (FHD) caused by mutations in
the FH gene results in fumaric aciduria, and common clinical
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DOI 10.1007/s10545-011-9294-8features observed are hypotonia, failure to thrive, severe
psychomotor retardation, seizures, facial dysmorphism and
brain malformations. Interestingly, whereas homozygous FH
mutations predispose to fumaric aciduria, several heterozy-
gous FH mutations are known to be involved in the
autosomal dominant syndrome of multiple cutaneous and
uterine leiomyomata (MCUL1) (Tomlinson et al. 2002).
Affected individuals develop benign smooth muscle tumours
of the skin, and females develop fibroids of the uterus. When
co-existing with an aggressive form of renal cell carcinoma
(papillary renal type II cancer or renal collecting duct cancer)
it is also known as hereditary leiomyomatosis and renal
cancer (HLRCC) syndrome. In MCUL1/HLRCC germline
mutations in FH are detected in the majority of the screened
cases. To date, 107 variants have been described, of which
93 are thought to be pathogenic (Bayley et al. 2008). The
most common types are missense mutations (57%), followed
by frameshift and nonsense mutations (27%), as well as
diverse deletions, insertions and duplications.
Here we present the crystal structure of human fumarase at
1.95Åresolutionandsummarizestructure-activitycorrelation
between observed mutations and clinical phenotypes.
Materials and methods
Expression, purification & crystallization
DNA fragment encoding the fumerase domain of human FH
(aa 44-510; GenBank entry 19743875) was subcloned into
Table 1 X-ray data collection and refinement statistics
Data collection
Space group P3221
a, b, c (Å) 188.5, 188.5, 114.6
γ 120
o
Wavelength (Å) 1.000
Resolution (Å)
* 25.0 – 1.95 (2.06 – 1.95)
Rmerge (%)
* 0.141 (0.732)
I/σI
* 9.7 (2.0)
Completeness (%)
* 99.3 (96.8)
Redundancy
* 6.2 (5.0)
Refinement
Resolution (Å) 41.27 – 1.90
No. reflections 168629
Rwork/Rfree (%) 19.7/24.4
No. atoms
Protein 13160
Ligand/ion 12
Water 655
B-factors (Å
2)
Main-chain 24.88
Side-chain and water 25.91
RMS deviations
Bond lengths (Å) 0.010
Bond angles (°) 1.201
PDB code 3E04 (doi:10.2210/pdb3e04/pdb)
* Numbers in parentheses represent data in the highest resolution shell.
Fig. 1 Ribbon/surface diagram
of human fumarate hydratase
illustrating the tetrameric
assembly of class II fumarases.
Molecular surface representation
is used to convey the overall
shape of each monomer as well
as the tetrameric assembly. Each
monomer has been coloured
distinctively, to facilitate
visualization. Two monomers
are represented using
semi-transparent surfaces, to
highlight the fold (represented
as ribbons). One of the active
sites is highlighted in red,
showing contribution of three
distinct subunits. The figures
were generated using the
program ICM
(www.molsoft.com)
672 J Inherit Metab Dis (2011) 34:671–676Table 2 Mutations observed in the human fumarase gene and
association to disease. Abbreviations: CL: cutaneous leiomyoma; FHD:
fumarate hydratase deficiency; HLRCC: hereditary leiomyomatosis and
renal cell cancer; LCT: Leydig cell tumors; MCUL: multiple cutaneous
and uterine leiomyomata; OMC: ovarian mucinous cystadenoma; RCC:
renal cell carcinoma; STS: soft tissue sarcoma; UL: uterine leiomyomas;
ULMS: uterine leiomyosarcoma
# Mutation
site
Mutated
residue
Protein
change
DNA
change
Exon Conservation Localization Reference Phenotype
1 Arg51 Glu R51E c.152 G>A 2 Conserved Surface (Kiuru et al. 2002) STS
2 Arg101 Pro R101P c.302 G>C 3 Semi-conserved Surface (Chan et al. 2005),
(Heinritz et al. 2008)
HLRCC
3 Asn107 Thr N107T c.320A>C 3 Conserved Active site (Tomlinson et al. 2002),
(Alam et al. 2005a),
(Carvajal-Carmona et al. 2006)
MCUL, LCT
4 Ala117 Pro A117P c.349 G>C 3 Semi-conserved Near active site (Tomlinson et al. 2002) MCUL
5 Leu132 Ser L132S c.395 T>C 4 Semi-conserved Surface (Wei et al. 2006) HLRCC, reduced
FH activity
6 His135 Arg H135R c.404A>G 4 Semi-conserved Surface (Chuang et al. 2005) MCUL
7 Gln142 Lys Q142K c.424 C>A 4 Conserved Near active site (Badeloe et al. 2006) MCUL
8 Ser158 Ile S158I c.473 G>T 4 Semi-conserved Near active site (Martinez-Mir et al. 2003) MCUL
9 Arg160 Gly R160G c.478A>G 4 Conserved Surface (Wei et al. 2006) MUCL, reduced
FH activity
10 Pro174 Arg P174R c.521 C>G 4 Not conserved Surface (Alam et al. 2005b),
(Zeng et al. 2006),
(Pollard et al. 2005)
FHD
11 His180 Arg H180R c.539A>G 4 Semi-conserved Active site (Tomlinson et al. 2002),
(Alam et al. 2005b)
MUCL
12 Gln185 Arg Q185R c.554A>G 4 Conserved Active site (Tomlinson et al. 2002) MCUL
13 Ser187 Leu S187L c.560C>T 5 Conserved Active site (Toro et al. 2003) MCUL
14 Asn188 Ser N188S c.563A>G 5 Conserved Active site (Toro et al. 2003) MCUL
15 Pro192 Leu P192L c.575A>G 5 Conserved In core helice (Chuang et al. 2005) MCUL
16 Met195 Thr M195T c.584 T>C 5 Conserved In core helice (Toro et al. 2003) MCUL
17 His196 Arg H196R c.587A>G 5 Conserved In core helice (Kiuru et al. 2002),
(Lehtonen et al. 2004)
RCC, ULMS
18 Ile229 Thr I229T c.686 T>C 5 Not conserved Surface (Alam et al. 2005b) MCUL
19 Lys230 Arg K230R c.689A>G 5 Conserved Subunit stabilization (Tomlinson et al. 2002),
(Coughlin et al. 1998),
(Manning et al. 2000)
FHD
20 Arg233 Cys R233C c.697 C>T 5 Conserved Active site (Rustin et al. 1997),
(Chuang et al. 2005),
(Wei et al. 2006)
FHD, HLRCC,
MCUL
21 Arg233 His R233H c.698 G>A 5 Conserved Active site (Tomlinson et al. 2002),
(Alam et al. 2005b), (Wei et al.
2006), (Chuang et al. 2005),
(Toro et al. 2003)
HLRCC, MCUL
22 Arg233 Leu R233L c.698 G>T 5 Conserved Active site (Chuang et al. 2005),
(Toro et al. 2003)
MCUL
23 Ala239 Thr A239T c.715 G>A 5 Conserved Near active site (Lehtonen et al. 2004)U L
24 Ala274 Thr A274T c.820 G>A 6 Not conserved Active site (Ylisaukko-oja et al. 2006) OMC
25 Gly282 Val G282V c.845 G>T 6 Conserved Active site (Tomlinson et al. 2002),
(Alam et al. 2005b)
MCUL
26 Ala308 Thr A308T c.922 G>A 7 Conserved Surface (Coughlin et al. 1998) FHD
27 Asn310 Tyr N310Y c.928A>T 7 Conserved Surface (Alam et al. 2005b) MCUL
28 Phe312 Cys F312C c.935 T>G 7 Conserved Surface (Coughlin et al. 1998) FHD
29 His318 Tyr H318Y c.952 C>T 7 Semi-conserved In core helice (Toro et al. 2003),
(Martinez-Mir et al. 2003)
HLRCC
30 His318 Leu H318L c.953A>T 7 Semi-conserved In core helice (Deschauer et al. 2006) FHD
31 Val322 Asp V322D c.964 T>A 7 Conserved In core helice (interaction
with 1 other monomer)
(Toro et al. 2003) MCUL
32 Thr330 Pro T330P c.988A>C 7 Semi-conserved In core helice (interaction
with 1 other monomer)
(Chuang et al. 2005) MCUL
33 Cys333 Tyr C333Y c.998 G>A 7 Semi-conserved In core helice (interaction
with 1 other monomer)
MCUL
34 Ser334 Arg S334R c.1002 T>G 7 Conserved In core helice (interaction
with 1 other monomer)
(Badeloe et al. 2006)C L
35 Leu335 Pro L335P c.1004 T>C 7 Conserved In core helice (Toro et al. 2003) MCUL
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# Mutation
site
Mutated
residue
Protein
change
DNA
change
Exon Conservation Localization Reference Phenotype
36 Asn340 Lys N340K c.1020 T>A 7 Semi-conserved In core helice (Toro et al. 2003),
(Wei et al. 2006)
MCUL
37 Glu355 Lys E355K c.1063 G>A 7 Conserved Subunit stabilization (Alam et al. 2005b) MCUL
38 Asn361 Lys N361K c.1083 T>A 7 Conserved Active site (Alam et al. 2005b) HLRCC-CDC
39 Glu362 Gln E362Q c.1084 G>C 7 Conserved Active site (Bourgeron et al. 1994) FHD
40 Ser365 Gly S365G c.1093 G>A 7 Conserved Active site (Toro et al. 2003),
(Wei et al. 2006)
MCUL
41 Ser366 Asn S366N c.1097 G>A 7 Conserved Active site (but out) (Toro et al. 2003),
(Alam et al. 2005b)
MCUL
42 Met368 Thr M368T c.1103 T>C 7 Conserved Active site (Badeloe et al. 2006) MCUL
43 Pro369 Ser P369S c.1105 C>T 7 Conserved Active site (but out) (Maradin et al. 2006) FHD
44 Asn373 Ser N373S c.1118A>G 8 Conserved Active site (Lehtonen et al. 2004) HLRCC/clear
cell RCC
45 Gln376 Pro Q376P c.1127A>C 8 Conserved In core helice (interaction
with 1 other monomer)
(Zeman et al. 2000),
(Remes et al. 2004),
(Phillips et al. 2006)
FHD
46 Ala385 Asp A385D c.1154 C>A 8 Not conserved In core helice (interaction
with 2 other monomers)
(Wei et al. 2006) MCUL
47 Val394 Leu V394L c.1180 G>C 8 Not conserved In core helice (Martinez-Mir et al. 2003) MCUL
48 Gly397 Arg G397R c.1189 G>A 8 Semi- conserved In core helice (Alam et al. 2005b) MCUL
49 His402 Cys H402C c.1207 C>T 8 Conserved In core helice turn (interaction
with 2 other monomers)
(Phillips et al. 2006) FHD
50 Ser419 Pro S419P c.1255 T>C 9 Conserved In core helice (Wei et al. 2006) HLRCC
51 Asp425 Val D425V c.1274A>T 9 Conserved In core helice (interaction
with 1 other monomer)
(Coughlin et al. 1998) FHD
52 Gln439 Pro Q439P c.1316A>C 9 Not conserved Surface (Wei et al. 2006) HLRCC
53 Met454 Ile M454I c.1362 G>A 9 Conserved Subunit interaction (Carvajal-Carmona et al. 2006) LCT
54 Tyr465 Cys Y465C c.1394A>G 10 Semi- conserved Surface (Toro et al. 2003) MCUL
55 Leu507 Pro L507P c.1520 T>C 10 Semi- conserved Surface near opening
active site
(Alam et al. 2005b) MCUL
Fig. 2 Clustering of human
fumarase missense mutations
observed in FHD, MCUL1 and
HLRCC. The active site is
highlighted in cyan. Positions of
amino acid mutations are
indicated as small spheres and
numbered according to Table 2.
The positions around the active
site are indicated in red,
mutations affecting inter-
or intrasubunit interactions are
indicated in dark yellow. For
clarity, one monomeric subunit
is omitted
674 J Inherit Metab Dis (2011) 34:671–676pNIC28-Bsa4 vector incorporating an N-terminal His6-tag. The
plasmid was transformed into BL21(DE3)-pRARE, cultured
in Terrific Broth at 37°C, and induced with 0.1 mM IPTG
overnight at 18°C. Cells were homogenized in lysis buffer
(50 mM K-phosphate pH 7.5, 500 mM NaCl, 1 mM TCEP),
centrifuged to remove cell debris, and the supernatant was
purified by Nickel affinity (HisTrap Crude FF) and size
exclusion (HiLoad 16/60 Superdex S200) chromatography.
Purified protein was concentrated to 12.6 mg/ml and stored
in 10 mM HEPES pH 7.5, 150 mM NaCl, 5% (w/v) glycerol
and 0.5 mM TCEP at -80°C. Crystals were grown by vapour
diffusion at 20°C in sitting drops mixing 150 nl protein and
150 nl reservoir solution containing 20% (w/v) PEG 3350,
0.2 M sodium acetate, 10% (w/v) ethylene glycol and
100 mM Bis-Tris propane pH 7.5. Crystals were cryo-
protected in mother liquor containing 25% (w/v) glycerol
and flash-frozen in liquid nitrogen.
Data collection & structure determination
Diffraction data to maximum resolution of 1.95 Å were
collected on beamline X10A at the Swiss Light Source, and
processed using the CCP4 Program suite (CCP4, 1994). FH
crystallized in the trigonal space group P3221 (a=180.5 Å,
b=180.5 Å, c=114.6 Å, α=90
o, β=90
o, γ=120
o)w i t hf o u r
molecules in the asymmetric unit. The structure of FH was
solved by molecular replacement with PHASER (McCoy et
al. 2005), using the yeast fumerase structure as search model
(PDB code 1YFM). Initial automated model building was
performed with ARP/wARP (Perrakis et al. 1999). This is
followed by cycles of iterative manual model building using
COOT (Emsley & Cowtan 2004) and restrained refinement
using REFMAC5 with TLS parameters (Murshudov et al.
1997). The final structure was deposited in the Protein Data
Bank (www.rcsb.org) under accession code 3E04 (Table 1).
Results and discussion
Fumarases are divided into two distinct groups. Class I
fumarases are iron-dependent iron-sulfur cluster containing,
dimeric enzymes, whereas the class II enzymes, including
human and other eukaryotic fumarases, are homotetrameric
enzymes with a molecular mass of about 200 kDa. Class II
fumarases are evolutionarily highly conserved enzymes, e.g.
the pairwise identity between E. coli and human fumarase is
about 60%. Every monomer exhibits a typical tridomain
structure, with a central domain involved in subunit
interaction, thus forming a typical bundle comprised of 20
α-helices (Fig. 1A). Previous crystallographic analyses have
revealed two distinct sites (A and B) in E. coli fumarase that
can bind carboxylic acids. Site A is formed from three
different monomer chains and likely to be the catalytic site,
whereas site B is thought to allosterically regulate activity
(Rose and Weaver 2004).
A previous study correlated 27 distinct missense muta-
tions to the E. coli fumarase structure (Alam 2005b), since
then the list of mutations has doubled. To this end, 55
missense mutations in the human fumarase gene are now
described. Here we correlate this updated list of mutations
to fumarase deficiency, MCUL1 and HLRCC syndrome
(Table 2) by using the human fumarase structure. Although
not all of these novel mutations have been biochemically
characterized, previous results suggest that FH activity is
related to HLRCC (Alam 2005a), although other environ-
mental or genetic factors likely play a role in the etiology of
the disease. The clustering of mutational “hotspots”
suggests enzyme activity relationships to phenotypic
appearances. Figure 2 illustrates the clustering of FH
mutations observed in FHD, MCUL1 and HLRCC. The
large majority of mutations are located at evolutionarily
highly conserved positions (Table 2) indicating that these
mutations likely affect stability and/or activity of the
enzyme. Two major clusters of mutations are observed;
one is likely to affect structural integrity of the enzyme by
interrupting inter or intrasubunit interactions (indicated in
yellow in Fig. 2), whereas the other mutations are located
around the active site and likely directly affect activity.
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